Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Prepaid Assets (2020 - 2025)

Historic Prepaid Assets for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $6.3 million.

  • Barinthus Biotherapeutics' Prepaid Assets fell 2254.28% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year decrease of 2254.28%. This contributed to the annual value of $6.2 million for FY2024, which is 3738.77% down from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Prepaid Assets stood at $6.3 million, which was down 2254.28% from $7.7 million recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Prepaid Assets peaked at $11.7 million during Q2 2022, and registered a low of $3.4 million during Q1 2021.
  • Moreover, its 5-year median value for Prepaid Assets was $7.7 million (2025), whereas its average is $7.6 million.
  • Its Prepaid Assets has fluctuated over the past 5 years, first soared by 35862.31% in 2021, then tumbled by 3738.77% in 2024.
  • Over the past 5 years, Barinthus Biotherapeutics' Prepaid Assets (Quarter) stood at $6.5 million in 2021, then increased by 27.95% to $8.3 million in 2022, then rose by 19.82% to $9.9 million in 2023, then crashed by 37.39% to $6.2 million in 2024, then grew by 2.14% to $6.3 million in 2025.
  • Its Prepaid Assets stands at $6.3 million for Q3 2025, versus $7.7 million for Q2 2025 and $6.3 million for Q1 2025.